FIH Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy

Overview

About this study

The purpose of this study is to test whether a single stereotactic intracerebral administration of inhibitory nerve cells into subjects with drug-resistant mesial temporal lobe epilepsy is safe (frequency of adverse events) and effective (seizure frequency).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

1. Male or Female, age ≥18 to 65

2. Focal seizures, clinically defined as TLE

3. Has failed to achieve seizure control despite adequate trials of at least 2 ASDs at
appropriate doses

4. Currently on stable doses (at least 1 month) of approved ASDs

5. Single seizure focus confirmed as within one temporal lobe

6. For subjects entering Stage 1, the seizure focus is either a) in the non-dominant
hemisphere, or b) in the dominant hemisphere and the subject has a Rey Auditory Verbal
Learning Test (RAVLT) assessed within one year of screening, or at the screening
visit, that is at least 1.5 standard deviations below the population mean.

7. Seizure frequency averages ≥2 per 28-day period over the 6 months prior to screening.

Exclusion Criteria:

1. Epilepsy due to other and/or progressive neurologic disease

2. Significant other medical condition which would impair safe participation

3. Primary or secondary immunodeficiency

4. Suicide attempt in the past year

5. Severe psychiatric disorders

6. Chronic indwelling intracranial device

7. MRI indicating potential malignant lesion

8. Pregnancy, or currently breastfeeding

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 12/20/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Jonathon Parker, M.D., Ph.D.

Open for enrollment

Contact information:

Kayla Haeger R.N.

(480) 342-5075

Haeger.Kayla@mayo.edu

More information

Publications

Publications are currently not available